AI Article Synopsis
- Tezepelumab significantly improved lung function in patients with severe, uncontrolled asthma over 52 weeks, showing better results compared to placebo in several key measurements, including pre-bronchodilator FEV and post-bronchodilator FEV.
- The NAVIGATOR study, which involved a double-blind, placebo-controlled design, treated patients aged 12-80 who were already on high-dose inhaled corticosteroids and other medications, with a randomized allocation to either tezepelumab or placebo.
- Results indicated that improvements in lung function were seen early and maintained throughout the study, especially in patients with shorter disease duration and specific baseline lung function conditions.
Article Abstract
Introduction: Severe asthma is associated with airway inflammation and airway obstruction. In the phase 3 NAVIGATOR study, tezepelumab treatment significantly improved pre-bronchodilator forced expiratory volume in 1 s (FEV) compared with placebo in patients with severe, uncontrolled asthma. This analysis assessed the effect of tezepelumab versus placebo on additional lung function parameters in patients from NAVIGATOR.
Methods: NAVIGATOR was a multicenter, randomized, double-blind, placebo-controlled study. Patients (12-80 years old) receiving medium- or high-dose inhaled corticosteroids and at least one additional controller medication, with or without oral corticosteroids, were randomized 1:1 to tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Changes from baseline to week 52 in pre-bronchodilator FEV, post-bronchodilator FEV, forced vital capacity (FVC), pre-bronchodilator FEV/FVC ratio, pre-bronchodilator forced expiratory flow between 25 and 75% of vital capacity (FEF), and morning and evening peak expiratory flow (PEF) were assessed.
Results: Tezepelumab treatment improved all evaluated lung function parameters over 52 weeks compared with placebo [least-squares mean difference (95% confidence interval): pre-bronchodilator FEV, 0.13 (0.08, 0.18) L; post-bronchodilator FEV, 0.12 (0.07, 0.16) L; FVC, 0.13 (0.07, 0.19) L; FEV/FVC ratio, 2.06% (1.22%, 2.90%); FEF, 0.13 (0.07, 0.19) L/s; morning PEF, 16.6 (8.1, 25.1) L/min; and evening PEF, 14.9 (6.3, 23.4) L/min]. Improvements were observed as early as weeks 1-2 and were maintained over 52 weeks. Greater improvements in lung function compared with placebo were observed in patients with a disease duration of less than 20 years, those with baseline post-bronchodilator FEV reversibility of at least 20%, and in patients with a baseline post-bronchodilator FEV/FVC ratio of less than 0.7.
Conclusion: These findings further support the benefits of tezepelumab treatment in improving airflow limitation in patients with severe, uncontrolled asthma.
Clinical Trial Registration: NAVIGATOR (NCT03347279).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567907 | PMC |
| http://dx.doi.org/10.1007/s12325-023-02659-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progress report on multiple endocrine neoplasia type 1.
Fam Cancer
January 2025
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Multiple endocrine neoplasia type 1 (MEN1) syndrome is an autosomal dominant disorder caused by a germline pathogenic variant in the MEN1 tumor suppressor gene. Patients with MEN1 have a high risk for primary hyperparathyroidism (PHPT) with a penetrance of nearly 100%, pituitary adenomas (PitAd) in 40% of patients, and neuroendocrine neoplasms (NEN) of the pancreas (40% of patients), duodenum, lung, and thymus. Increased MEN1-related mortality is mainly related to duodenal-pancreatic and thymic NEN.
View Article and Find Full Text PDFNanoscale Viscometry Reveals an Inherent Mucus Defect in Cystic Fibrosis.
ACS Nano
January 2025
Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec H2X 0A9, Canada.
The abnormally viscous and thick mucus is a hallmark of cystic fibrosis (CF). How the mutated CF gene causes abnormal mucus remains an unanswered question of paramount interest. Mucus is produced by the hydration of gel-forming mucin macromolecules that are stored in intracellular granules prior to release.
View Article and Find Full Text PDFImpact of time to treatment initiation on the development of cachexia and clinical outcomes in lung cancer.
Jpn J Clin Oncol
January 2025
Department of Thoracic Oncology, Kansai Medical University, 2-3-1 Shinmachi, Hirakata city, Osaka 573-1191, Japan.
Background: Pre-cancer onset of cachexia raises uncertainties regarding the optimal timing for early intervention in lung cancer patients. We aimed to examine changes in physical function, nutritional status, and cachexia incidence in patients with lung cancer from the initial visit to treatment initiation and determine the effect of these changes on lung cancer treatment.
Methods: This single-center retrospective cohort study enrolled patients suspected of having advanced lung cancer who visited Kansai Medical University Hospital between January and February 2023 and were definitely diagnosed with the disease.
Reversion of Supra-Ventricular Tachycardia Through High Positive End-Expiratory Pressure During Mechanical Ventilation in Critically Ill Patients.
J Coll Physicians Surg Pak
January 2025
Department of Emergency Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
The Valsalva manoeuvre is widely recognised for its effectiveness in reverting supra-ventricular tachycardia (SVT) in patients with good coordination. However, this is not applicable in sedated ventilated patients and there is a dearth of literature regarding the application of Valsalva in unconscious patients on mechanical ventilation. The authors, for the first time, present a novel non-pharmacological method to treat SVT in critically ill patients on mechanical ventilation, employing the high positive end-expiratory pressure (PEEP) technique.
View Article and Find Full Text PDFIndividualized PEEP titration by lung compliance during one-lung ventilation: a meta-analysis.
Crit Care
January 2025
Department of Intensive Care Unit, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Background: Despite the physiological advantages of positive end-expiratory pressure (PEEP), its optimal utilization during one-lung ventilation (OLV) remains uncertain. We aimed to investigate whether individualized PEEP titration by lung compliance is associated with a reduced risk of postoperative pulmonary complications during OLV.
Methods: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials until April 1, 2024, to identify published randomized controlled trials that compared individualized PEEP titration by lung compliance with fixed PEEP during OLV.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!